STEVE YANG: Open Payments
NPI 1770070781 · GLENDORA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,271 in 96 payments from 12 companies in 2025. Trend: 2023 $2,870 · 2024 $3,189 · 2025 $2,271
Food & beverage: $2,271
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 17 | $469 |
| Vanda Pharmaceuticals Inc. | 12 | $379 |
| Neurocrine BioSciences, Inc. | 18 | $302 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $247 |
| Teva Pharmaceuticals USA, Inc. | 8 | $241 |
| E.R. Squibb & Sons, L.L.C. | 9 | $199 |
| Otsuka America Pharmaceutical, Inc. | 10 | $198 |
| Gilead Sciences, Inc. | 1 | $121 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| ABBVIE INC. | 2 | $31 |
Products named: ARISTADA, HETLIOZ, INGREZZA, CAPLYTA, COBENFY, REXULTI, UZEDY, Yeztugo.
Industry payments across CA — which companies pay providers there.
